Top

Published in:

01-12-2005 | Review

Molecular genetic alterations in gliomatosis cerebri: What can we learn about the origin and course of the disease?

Author: Christian Mawrin

Published in: Acta Neuropathologica | Issue 6/2005

Abstract

Gliomatosis cerebri (GC) is a neuroepithelial neoplasm with extensive infiltration of large parts of the brain. Recent data showing the involvement of TP53 mutation or nuclear protein accumulation in some cases have linked the astrocytic phenotype of the tumor cells to TP53 alterations frequently found in common astrocytomas. However, the frequency of these alterations is low, and other molecular genetic changes have been only rarely identified. Those found in common high-grade astrocytomas and glioblastomas are usually missing in GC. The distribution of TP53 point mutations, as well as non-coding polymorphic markers and some cytogenetic data, support a monoclonal origin in some cases, and are at least compatible with it in most cases, while no conclusive data suggesting a polyclonal origin have been reported. This raises the question of mechanisms responsible for the enhanced infiltrative potential of the tumor cells in this disease, which have not yet been identified.

Ariza A, Lopez D, Mate JL, Isamat M, Musulen E, Pujol M, Ley A, Navas-Palacios JJ (1995) Role of CD44 in the invasiveness of glioblastoma multiforme and the noninvasiveness of meningioma: an immunohistochemistry study. Hum Pathol 26:1144–1147CrossRefPubMed

Artigas J, Cervos-Navarro J, Iglesias JR, Ebhardt G (1985) Gliomatosis cerebri: clinical and histological findings. Clin Neuropathol 4:135–148PubMed

Asher R, Bignami A (1992) Hyaluronate binding and CD44 expression in human glioblastoma cells and astrocytes. Exp Cell Res 203:80–90CrossRefPubMed

Balko MG, Blisard KS, Samaha FJ (1992) Oligodendroglial gliomatosis cerebri. Hum Pathol 23:706–707CrossRefPubMed

Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, Knyazeva T, Muller S, Gartner S, Sures I, Wang H, Imyanitov E, Haring HU, Knayzev P, Iacobelli S, Hofler H, Ullrich A (2002) Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 62:840–847PubMed

Benjelloun A, Delavelle J, Lazeyras F, Dietrich PY (2001) Possible efficacy of temozolomide in a patient with gliomatosis cerebri. Neurology 57:1932–1933PubMed

Burke D, Wilkes D, Blundell TL, Malcolm S (1998) Fibroblast growth factor receptors: lessons from the genes. Trends Biochem Sci 23:59–62CrossRefPubMed

Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479CrossRefPubMed

Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM (1997) Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3:227–230CrossRefPubMed

10.

Cavenee WK, Furnari FB, Nagane M, Huang HJS, Newcomb EW, Bigner DD, Weller M, Berens ME, Plate KH, Israel MA, Noble MD, Kleihues P (2000) Astrocytic tumours. In: Kleihues P, Cavenee WK (eds) Pathology and genetics: Tumours of the Nervous System. IARC Press, Lyon, pp 9–39

11.

Cervos-Navarro J, Artigas J, Aruffo C, Iglesias J (1987) The fine structure of gliomatosis cerebri. Virchows Arch [A] 411:93–98

12.

Cummings TJ, Hulette CM, Longee DC, Bottom KS, McLendon RE, Chu CT (1999) Gliomatosis cerebri: cytologic and autopsy findings in a case involving the entire neuraxis. Clin Neuropathol 18:190–197PubMed

13.

Elshaikh MA, Stevens GH, Peereboom DM, Cohen BH, Prayson RA, Lee SY, Barnett GH, Suh JH (2002) Gliomatosis cerebri. Cancer 95:2027–2031CrossRefPubMed

14.

Foerster O, Gagel O (1934) Zentrale diffuse Schwannose bei Recklinghausenscher Krankheit. Z Gesamte Neurol Psychiatr 151:1–16

15.

Galanaud D, Chinot O, Nicoli F, Confort-Gouny S, Le Fur Y, Barrie-Attarian M, Ranjeva JP, Fuentes S, Viout P, Figarella-Branger D, Cozzone PJ (2003) Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. J Neurosurg 98:269–276PubMed

16.

Gutowski NJ, Gomez-Anson B, Torpey N, Revesz T, Miller D, Rudge P (1999) Oligodendroglial gliomatosis cerebri: (1)H-MRS suggests elevated glycine/inositol levels. Neuroradiology 41:650–653CrossRefPubMed

17.

Hecht BK, Turc-Carel C, Chatel M, Lonjon M, Roche JL, Gioanni J, Hecht F, Gaudray P (1995) Chromosomes in gliomatosis cerebri. Genes Chromosomes Cancer 14:149–153PubMed

18.

Herrlinger U, Felsberg J, Küker W, Bornemann A, Plasswilm L, Knobbe CB, Strik H, Wick W, Meyermann R, Dichgans J, Bamberg M, Reifenberger G, Weller M (2002) Gliomatosis cerebri: molecular pathology and clinical course. Ann Neurol 52:390–399CrossRefPubMed

19.

Horst E, Micke O, Romppainen ML, Pyhtinen J, Paulus W, Schafer U, Rube C, Willich N (2000) Radiation therapy approach in gliomatosis cerebri—case reports and literature review. Acta Oncol 39:747–751CrossRefPubMed

20.

Jennings MT, Frenchman M, Shehab T, Johnson MD, Creasy J, LaPorte K, Dettbarn WD (1995) Gliomatosis cerebri presenting as intractable epilepsy during early childhood. J Child Neurol 10:37–45PubMed

21.

Jezequel P, Campion L, Joalland MP, Millour M, Dravet F, Classe JM, Delecroix V, Deporte R, Fumoleau P, Ricolleau G (2004) G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. Br J Cancer 90:189–193CrossRefPubMed

22.

Kannuki S, Hirose T, Horiguchi H, Kageji T, Nagahiro S (1998) Gliomatosis cerebri with secondary glioblastoma formation: report of two cases. Brain Tumor Pathol 15:111–116PubMed

23.

Kattar MM, Kupsky WJ, Shimoyama RK, Vo TD, Olson MW, Bargar GR, Sarkar FH (1997) Clonal analysis of gliomas. Hum Pathol 28:1166–1179CrossRefPubMed

24.

Kim DG, Yang HJ, Park IA, Chi JG, Jung HW, Han DH, Choi KS, Cho BK (1998) Gliomatosis cerebri: clinical features, treatment, and prognosis. Acta Neurochir (Wien) 140:755–762

25.

Kirches E, Michael M, Woy C, Schneider T, Warich-Kirches M, Schneider-Stock R, Winkler K, Wittig H, Dietzmann K (1999) Loss of heteroplasmy in the displacement loop of brain mitochondrial DNA in astrocytic tumors. Genes Chromosomes Cancer 26:80–83CrossRefPubMed

26.

Kirches E, Krause G, Warich-Kirches M, Weis S, Schneider T, Meyer-Puttlitz B, Mawrin C, Dietzmann K (2001) High frequency of mitochondrial DNA mutations in glioblastoma multiforme identified by direct sequence comparison to blood samples. Int J Cancer 93:534–538CrossRefPubMed

27.

Kirches E, Mawrin C, Schneider-Stock R, Krause G, Scherlach C, Dietzmann K (2003) Mitochondrial DNA as a clonal tumor cell marker: gliomatosis cerebri. J Neurooncol 61:1–5CrossRefPubMed

28.

Kleihues P, Ohgaki H (1999) Primary and secondary glioblastomas: from concept to clinical diagnosis. Neurooncology 1:44–51

29.

Kros JM, Zheng P, Dinjens WN, Alers JC (2002) Genetic aberrations in gliomatosis cerebri support monoclonal tumorigenesis. J Neuropathol Exp Neurol 61:806–814PubMed

30.

Kunishio K, Okada M, Matsumoto Y, Nagao S (2003) Matrix metalloproteinase-2 and −9 expression in astrocytic tumors. Brain Tumor Pathol 20:39–45PubMed

31.

Kuppner MC, Van Meir E, Gauthier T, Hamou MF, Tribolet N de (1992) Differential expression of the CD44 molecule in human brain tumours. Int J Cancer 50:572–577PubMed

32.

Lantos PL, Bruner JM (2000) Gliomatosis cerebri. In: Kleihues P, Cavenee WK (eds) Pathology and genetics: Tumours of the Nervous System. IARC Press, Lyon, pp 92–93

33.

Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein P, Weis S (2003) Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer 98:2430–2439CrossRefPubMed

34.

Levin N, Gomori JM, Siegal T (2004) Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide. Neurology 63:354–356PubMed

35.

Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M (1997) Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3:231–234CrossRefPubMed

36.

Lodi R, Setola E, Tonon C, Ambrosetto P, Franceschi E, Crino L, Barbiroli B, Cortelli P (2003) Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration. Magn Reson Imaging 21:1003–1007CrossRefPubMed

37.

Mawrin C, Aumann V, Kirches E, Schneider-Stock R, Scherlach C, Vogel S, Mittler U, Dietzmann K (2001) Gliomatosis cerebri: post-mortem molecular and immunohistochemical analyses in a case treated with thalidomide. J Neurooncol 55:11–17CrossRefPubMed

38.

Mawrin C, Kirches E, Schneider-Stock R, Scherlach C, Vorwerk C, Deimling A von, Landeghem F van, Meyermann R, Bornemann A, Müller A, Romeike B, Stoltenburg-Didinger G, Wickboldt J, Pilz P, Dietzmann K (2003) Analysis of TP53 and PTEN in gliomatosis cerebri. Acta Neuropathol 105:529–536PubMed

39.

Mawrin C, Lins H, Kirches E, Schildhaus HU, Scherlach C, Kanakis D, Dietzmann K (2003) Distribution of p53 alterations in a case of gliomatosis cerebri. Hum Pathol 34:102–106CrossRefPubMed

40.

Mawrin C, Kirches E, Schneider-Stock R, Boltze C, Vorwerk CK, Deimling A von, Stoltenburg-Didinger G, Bornemann A, Romeike B, Sellhaus B, Dietzmann K (2005) Alterations of cell cycle regulators in gliomatosis cerebri. J Neurooncol 72:115–122CrossRefPubMed

41.

Mawrin C, Schneider T, Firsching R, Wiedemann FR, Dietzmann K, Bornemann A, Romeike B, Sellhaus B, Deimling A von (2005) Assessment of tumor cell invasion factors in gliomatosis cerebri. J Neurooncol 73:109–115CrossRefPubMed

42.

Morimoto Y, Ozaki T, Ouchida M, Umehara N, Ohata N, Yoshida A, Shimizu K, Inoue H (2003) Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 98:2245–2250CrossRefPubMed

43.

Nagasaka S, Tanabe KK, Bruner JM, Saya H, Sawaya RE, Morrison RS (1995) Alternative RNA splicing of the hyaluronic acid receptor CD44 in the normal human brain and in brain tumors. J Neurosurg 82:858–863PubMed

44.

Nakano A, Tani E, Miyazaki K, Yamamoto Y, Furuyama J (1995) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg 83:298–307PubMed

45.

Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P (1991) p53 mutations in nonastrocytic human brain tumors. Cancer Res 51:6202–6205PubMed

46.

Oz B, Karayel FA, Gazio NL, Ozlen F, Balci K (2000) The distribution of extracellular matrix proteins and CD44S expression in human astrocytomas. Pathol Oncol Res 6:118–124PubMed

47.

Piva R, Cavalla P, Bortolotto S, Cordera S, Richiardi P, Schiffer D (1997) p27/kip1 expression in human astrocytic gliomas. Neurosci Lett 234:127–130CrossRefPubMed

48.

Sanchez-Cespedes M, Parrella P, Nomoto S, Cohen D, Xiao Y, Esteller M, Jeronimo C, Jordan RC, Nicol T, Koch WM, Schoenberg M, Mazzarelli P, Fazio VM, Sidransky D (2001) Identification of a mononucleotide repeat as a major target for mitochondrial DNA alterations in human tumors. Cancer Res 61:7015–7019PubMed

49.

Sanson M, Cartalat-Carel S, Taillibert S, Napolitano M, Djafari L, Cougnard J, Gervais H, Laigle F, Carpentier A, Mokhtari K, Taillandier L, Chinot O, Duffau H, Honnorat J, Hoang-Xuan K, Delattre JY (2004) Initial chemotherapy in gliomatosis cerebri. Neurology 63:270–275PubMed

50.

Scheinker IM, Evans JP (1943) Diffuse cerebral glioblastosis. J Neuropathol Exp Neurol 2:78–189

51.

Scherer HJ (1940) Cerebral astrocytomas and their derivatives. Am J Cancer 40:159–197

52.

Schober R, Mai JK, Volk B, Wechsler W (1991) Gliomatosis cerebri: bioptical approach and neuropathological verification. Acta Neurochir (Wien) 113:131–137

53.

Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B (1992) Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355:846–847CrossRefPubMed

54.

Streit S, Bange J, Fichtner A, Ihrler S, Issing W, Ullrich A (2004) Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 111:213–217CrossRefPubMed

55.

Tancredi A, Mangiola A, Guiducci A, Peciarolo A, Ottaviano P (2000) Oligodendrocytic gliomatosis cerebri. Acta Neurochir (Wien) 142:469–472

56.

Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, Kleihues P, Ohgaki H (1998) PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 57:684–689PubMed

57.

Von Deimling A, Eibl RH, Ohgaki H (1992) p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytomas. Cancer Res 52:2987–2990PubMed

58.

Von Deimling A, Ammon K von, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN (1993) Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3:19–26PubMed

59.

Yamada SM, Hayashi Y, Takahashi H, Teramoto A, Matsumoto K, Yamada S (2001) Histological and genetic diagnosis of gliomatosis cerebri: case report. J Neurooncol 52:237–240CrossRefPubMed

60.

Yamaguchi F, Saya H, Bruner JM, Morrison RS (1994) Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci USA 91:484–488PubMed

61.

Ylagan LR, Quinn B (1997) CD44 expression in astrocytic tumors. Mod Pathol 10:1239–1246PubMed

Title: Molecular genetic alterations in gliomatosis cerebri: What can we learn about the origin and course of the disease?
Author: Christian Mawrin
Publication date: 01-12-2005
Publisher: Springer-Verlag
Published in: Acta Neuropathologica / Issue 6/2005
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-005-1083-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Molecular genetic alterations in gliomatosis cerebri: What can we learn about the origin and course of the disease?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2005

Peripheral nerve and skeletal muscle involvement in CADASIL

Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies

Mutational and immunohistochemical analysis of ezrin-, radixin-, moesin (ERM) molecules in epilepsy-associated glioneuronal lesions

Expression of an endoplasmic reticulum-resident chaperone, glucose-regulated stress protein 78, in the spinal cord of a mouse model of amyotrophic lateral sclerosis

Hypoxic-ischemic brain injury in infants with congenital heart disease dying after cardiac surgery

Microtubule-associated protein 2 (MAP2)—a promising approach to diagnosis of forensic types of hypoxia-ischemia